Skip to main content
Erschienen in: Current Hematologic Malignancy Reports 6/2017

24.10.2017 | Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN

verfasst von: Naveen Pemmaraju, Audun Utengen, Vikas Gupta, Michael A. Thompson, Andrew A. Lane

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The use of Twitter, one of the most commonly engaged social media platforms in the world, is increasing among the general public. Notably, this trend has also been observed among those involved in the healthcare field. With its ability to readily connect diverse groups of stakeholders in a given area of interest, Twitter has become a focal point for those involved in increasing awareness and information exchange in orphan disease fields. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy with generally poor long-term outcomes for adult patients and no standard therapeutic guidelines. Coupled with its low incidence rate, the disease has experienced a number of name changes over the past three decades (e.g., blastic NK cell lymphoma, CD4+CD56+ hematodermic tumor), thereby historically resulting in difficulties in its clinico-pathologic diagnosis and treatment approaches. All of these factors have led to a striking gap in terms of accurate information available to patients and the general public. Therefore, there is an urgent need for the development of more venues for the dissemination of information, particularly online, for this rare cancer.

Recent Findings

In this context, we began the Twitter medical community, #BPDCN, over a year ago, to help fill this information void.

Summary

Now, completing its first year of existence, we aimed to analyze the metrics of Twitter use in order to better understand and to describe the characteristics and reach in of #BPDCN, and to determine the feasibility of starting and maintaining a disease-specific hashtag community in a particularly rare cancer.
Literatur
1.
Zurück zum Zitat Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14:220–2.PubMed Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14:220–2.PubMed
2.
Zurück zum Zitat Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98:239–46.CrossRefPubMedPubMedCentral Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98:239–46.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Reimer P, Rudiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32:637–46.CrossRefPubMed Reimer P, Rudiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32:637–46.CrossRefPubMed
5.
Zurück zum Zitat Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMed Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMed
6.
Zurück zum Zitat Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol. 2016;91:283–6.CrossRefPubMed Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and HyperCVAD therapy. Am J Hematol. 2016;91:283–6.CrossRefPubMed
7.
Zurück zum Zitat Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88:1055–61.CrossRefPubMed Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88:1055–61.CrossRefPubMed
8.
Zurück zum Zitat Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMed Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMed
9.
Zurück zum Zitat Martin-Martin L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7:10174–81.CrossRefPubMedPubMedCentral Martin-Martin L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7:10174–81.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174:188–202.CrossRefPubMed Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174:188–202.CrossRefPubMed
11.
Zurück zum Zitat Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121:440–6.CrossRefPubMed Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121:440–6.CrossRefPubMed
12.
Zurück zum Zitat Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1006–12.CrossRefPubMed Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1006–12.CrossRefPubMed
13.
Zurück zum Zitat Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125:3559–62.CrossRefPubMed Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125:3559–62.CrossRefPubMed
14.
Zurück zum Zitat Pemmaraju N, Thomas D, Kantarjian HM, et al. Analysis of outcomes of patients with blastic plasmacytoid dendritic cell neoplasm. ASH Annual Meeting Abstracts 2012;120:3554. Pemmaraju N, Thomas D, Kantarjian HM, et al. Analysis of outcomes of patients with blastic plasmacytoid dendritic cell neoplasm. ASH Annual Meeting Abstracts 2012;120:3554.
15.
Zurück zum Zitat Frankel A. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. ASCO Annual Meeting 2013; J Clin Oncol (Meeting Abstracts) 2014;17;124(3):385–92. https://doi.org/10.1182/blood-2014-04-566737. Frankel A. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. ASCO Annual Meeting 2013; J Clin Oncol (Meeting Abstracts) 2014;17;124(3):385–92. https://​doi.​org/​10.​1182/​blood-2014-04-566737.
16.
Zurück zum Zitat Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer discovery. 2017;7:156–64.CrossRefPubMed Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer discovery. 2017;7:156–64.CrossRefPubMed
17.
Zurück zum Zitat Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30:764–78.CrossRefPubMedPubMedCentral Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30:764–78.CrossRefPubMedPubMedCentral
18.
19.
Zurück zum Zitat Sapienza MR, Fabio F, Claudio A, et al. Molecular profiling of blastic plasmacytoid dendritic CELL neoplasm reveals a unique pattern and suggests selective sensitivity to NF-KB pathway inhibition. Blood. 2013;122:2502. Sapienza MR, Fabio F, Claudio A, et al. Molecular profiling of blastic plasmacytoid dendritic CELL neoplasm reveals a unique pattern and suggests selective sensitivity to NF-KB pathway inhibition. Blood. 2013;122:2502.
21.
Zurück zum Zitat Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN)—focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015;10:413–20.CrossRefPubMed Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN)—focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015;10:413–20.CrossRefPubMed
22.
Zurück zum Zitat Katz MS, Utengen A, Anderson PF, Thompson MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol. 2015;33; suppl abstr:6520. Katz MS, Utengen A, Anderson PF, Thompson MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol. 2015;33; suppl abstr:6520.
23.
Zurück zum Zitat Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN)-focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015; Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN)-focus on twitter and the development of a disease-specific community: #MPNSM. Curr Hematol Malig Rep. 2015;
24.
Zurück zum Zitat Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN): analysis of advanced metrics from the first year of a new twitter community: #MPNSM. Curr Hematol Malig Rep. 2016;11:456–61.CrossRefPubMed Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (MPN): analysis of advanced metrics from the first year of a new twitter community: #MPNSM. Curr Hematol Malig Rep. 2016;11:456–61.CrossRefPubMed
26.
Zurück zum Zitat Katz MS, Utengen A, Anderson PF, et al. Disease-specific hashtags for online communication about cancer care. JAMA Oncol. 2016;2:392–4.CrossRefPubMed Katz MS, Utengen A, Anderson PF, et al. Disease-specific hashtags for online communication about cancer care. JAMA Oncol. 2016;2:392–4.CrossRefPubMed
27.
Zurück zum Zitat Pemmaraju Nea. Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood (ASH abstract #4245, Dec 2016)2016. Pemmaraju Nea. Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood (ASH abstract #4245, Dec 2016)2016.
28.
Zurück zum Zitat Pemmaraju N, Thompson MA, Mesa RA, Desai T. Analysis of the use and impact of twitter during American Society of Clinical Oncology annual meetings from 2011 to 2016: focus on advanced metrics and user trends. J oncol prac / Am Soc Clin Oncol. 2017;13:e623–e31.CrossRef Pemmaraju N, Thompson MA, Mesa RA, Desai T. Analysis of the use and impact of twitter during American Society of Clinical Oncology annual meetings from 2011 to 2016: focus on advanced metrics and user trends. J oncol prac / Am Soc Clin Oncol. 2017;13:e623–e31.CrossRef
Metadaten
Titel
Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN
verfasst von
Naveen Pemmaraju
Audun Utengen
Vikas Gupta
Michael A. Thompson
Andrew A. Lane
Publikationsdatum
24.10.2017
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 6/2017
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0422-x

Weitere Artikel der Ausgabe 6/2017

Current Hematologic Malignancy Reports 6/2017 Zur Ausgabe

Myelodysplastic Syndromes (M Savona, Section Editor)

Models of Prognostication in Chronic Myelomonocytic Leukemia

Acute Myeloid Leukemias (H Erba, Section Editor)

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia

Acute Myeloid Leukemias (H Erba, Section Editor)

Predicting Chemotherapy Resistance in AML

CART and Immunotherapy (M Ruella, Section Editor)

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer

Acute Myeloid Leukemias (H Erba, Section Editor)

Methods of Detection of Measurable Residual Disease in AML

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.